SIGA Technologies(SIGA) - 2024 Q4 - Annual Results

Financial Performance - SIGA reported $133 million in product sales for 2024, marking a growth from$130.7 million in 2023[4] - The company achieved a pre-tax operating income of $70 million and a net income of$59.2 million for the year ended December 31, 2024[4][5] - Total revenues for 2024 were $138.7 million, slightly down from$139.9 million in 2023[4] - Diluted earnings per share for 2024 were $0.82, compared to$0.95 in 2023[4] Product Sales and Market Expansion - Approximately $100 million of product sales were generated from oral and IV TPOXX to the U.S. Strategic National Stockpile, with$60 million recognized in Q4 2024[11] - SIGA received procurement orders for oral TPOXX from 30 countries over the past three years, with international sales to 13 countries in 2024[11] - TPOXX received regulatory approval in Japan in January 2025 for the treatment of smallpox and mpox, expanding its market reach[11] Future Revenue Potential - The company has approximately $70 million in outstanding procurement orders as it enters 2025, indicating potential future revenue[3] Financial Health - Total current assets decreased to$231 million in 2024 from $238.99 million in 2023[15] - Total liabilities significantly decreased to$28.53 million in 2024 from $57.49 million in 2023, reflecting improved financial health[15]